Zobrazeno 1 - 10
of 1 079
pro vyhledávání: '"Stahmann, A"'
Autor:
Ahmed Abdelhak, Kai Antweiler, Markus C. Kowarik, Makbule Senel, Joachim Havla, Uwe K. Zettl, Ingo Kleiter, Thomas Skripuletz, Axel Haarmann, Alexander Stahmann, Andre Huss, Stefan Gingele, Markus Krumbholz, Pascal Benkert, Jens Kuhle, Tim Friede, Albert C. Ludolph, Ulf Ziemann, Tania Kümpfel, Hayrettin Tumani
Publikováno v:
Annals of Clinical and Translational Neurology, Vol 11, Iss 2, Pp 477-485 (2024)
Abstract Objective Progression prediction is a significant unmet need in people with progressive multiple sclerosis (pwPMS). Studies on glial fibrillary acidic protein (GFAP) have either been limited to single center with relapsing MS or were based s
Externí odkaz:
https://doaj.org/article/017baefb71394890b530b34dca8c17fc
Autor:
Niklas Frahm, David Ellenberger, Alexander Stahmann, Firas Fneish, Daniel Lüftenegger, Hans C. Salmen, Ksenija Schirduan, Tom P. A. Schaak, Peter Flachenecker, Christoph Kleinschnitz, Friedemann Paul, Dagmar Krefting, Uwe K. Zettl, Melanie Peters, Clemens Warnke
Publikováno v:
Therapeutic Advances in Neurological Disorders, Vol 17 (2024)
Background: The spectrum of disease-modifying therapies (DMTs) for people with multiple sclerosis (PwMS) has expanded over years, but data on treatment strategies is largely lacking. DMT switches are common clinical practice. Objective: To compare sw
Externí odkaz:
https://doaj.org/article/c8eeaeea69924efc9284aba8da3cbdca
Autor:
Alexander Stahmann, Elaine Craig, David Ellenberger, Firas Fneish, Niklas Frahm, Ruth Ann Marrie, Rod Middleton, Richard Nicholas, Jeff Rodgers, Clemens Warnke, Amber Salter
Publikováno v:
Therapeutic Advances in Neurological Disorders, Vol 17 (2024)
Background: Treatment guidelines recommend early disease-modifying therapy (DMT) initiation after diagnosis of multiple sclerosis (MS). Multinational comparative studies that assess time to DMT initiation in MS may allow detection of barriers inheren
Externí odkaz:
https://doaj.org/article/85e9dcff225c45649ad0ca9d2536773d
Autor:
Abdelhak, Ahmed, Antweiler, Kai, Kowarik, Markus C., Senel, Makbule, Havla, Joachim, Zettl, Uwe K., Kleiter, Ingo, Hoshi, Muna-Miriam, Skripuletz, Thomas, Haarmann, Axel, Stahmann, Alexander, Huss, Andre, Gingele, Stefan, Krumbholz, Markus, Selge, Charlotte, Friede, Tim, Ludolph, Albert C., Overell, James, Koendgen, Harold, Clinch, Susanne, Wang, Qing, Ziemann, Ulf, Hauser, Stephen L., Kümpfel, Tania, Green, Ari J, Tumani, Hayrettin
Publikováno v:
In Multiple Sclerosis and Related Disorders January 2024 81
Publikováno v:
Therapeutic Advances in Neurological Disorders, Vol 16 (2023)
Background: Epileptic seizures can occur throughout the course of multiple sclerosis (MS) and are associated with increasing disability progression over time. However, there are no data on whether epileptic seizures at the onset of MS also lead to in
Externí odkaz:
https://doaj.org/article/840158c596c944f99abb9da57908da3f
Autor:
Richard Nicholas, Jeff Rodgers, James Witts, Annalaura Lerede, Tim Friede, Jan Hillert, Lars Forsberg, Anna Glaser, Ali Manouchehrinia, Ryan Ramanujam, Tim Spelman, Pernilla Klyve, Jiri Drahota, Dana Horakova, Hanna Joensen, Luigi Pontieri, Melinda Magyari, David Ellenberger, Alexander Stahmann, Helmut Butzkueven, Anneke Van Der Walt, Vladimir Bezlyak, Carol Lines, Rod Middleton
Publikováno v:
Therapeutic Advances in Neurological Disorders, Vol 16 (2023)
Introduction: Prescribing guidance for disease-modifying treatment (DMT) in multiple sclerosis (MS) is centred on a clinical diagnosis of relapsing–remitting MS (RRMS). DMT prescription guidelines and monitoring vary across countries. Standardising
Externí odkaz:
https://doaj.org/article/94019eea78bf46cdb31bf422481b6086
Autor:
Firas Fneish, Niklas Frahm, Melanie Peters, David Ellenberger, Judith Haas, Micha Löbermann, Dieter Pöhlau, Anna-Lena Röper, Sarah Schilling, Alexander Stahmann, Herbert Temmes, Friedemann Paul, Uwe K. Zettl
Publikováno v:
Vaccines, Vol 11, Iss 12, p 1859 (2023)
Several studies reported post-SARS-CoV-2-vaccination (PV) symptoms. Even people with multiple sclerosis (PwMS) have concerns about disease activity following the SARS-CoV-2 vaccination. We aimed to determine the proportion of PwMS with PV relapses, t
Externí odkaz:
https://doaj.org/article/fd7179958544494b9322499460d272e4
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Niklas Frahm, Firas Fneish, David Ellenberger, Judith Haas, Micha Loebermann, Tina Parciak, Melanie Peters, Dieter Pöhlau, Jeff Rodgers, Anna-Lena Röper, Sarah Schilling, Alexander Stahmann, Herbert Temmes, Uwe K. Zettl, Rodden M. Middleton
Publikováno v:
The Lancet Regional Health. Europe, Vol 22, Iss , Pp 100502- (2022)
Summary: Background: Vaccines offer people with multiple sclerosis (PwMS) an effective protection against severe COVID-19 disease courses. However, representative real-world data on the tolerability of SARS-CoV-2 vaccines in PwMS are limited. We aime
Externí odkaz:
https://doaj.org/article/9a6b3486974f4051a56463f363e21125
Autor:
Susanne Nieland, Susann Barig, Julian Salzmann, Frauke Gehrau, Arief Izzairy Zamani, Annabell Richter, Julia Ibrahim, Yvonne Gräser, Chyan Leong Ng, Klaus‐Peter Stahmann
Publikováno v:
Microbial Biotechnology, Vol 14, Iss 4, Pp 1422-1432 (2021)
Summary To set a benchmark in fungal growth rate, a differential analysis of prototrophic Aspergillus fumigatus AR04 with three ascomycetes applied in > 103 t year‐1 scale was performed, i.e. Ashbya gosspyii (riboflavin), Aspergillus niger (citric
Externí odkaz:
https://doaj.org/article/9df82ca8636147c7bda86fc81a8d5aad